COMMODORE CAPITAL LP
Q2 2025 Form 13-F
NEW YORK, NEW YORK
CIK 0001831942
· CRD 304370
· SEC-registered investment adviser
$1.4B Reported Value Total
COMMODORE CAPITAL reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $1,763,757,281, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-31
Reported value
$1.4B
Quarter over quarter
+7.2%
Holdings
33
Top-10 concentration
62.2%
Key People
Form ADV owners & control persons
Robert Egen Turrell Atkinson
LIMITED PARTNER
Michael Jonathan Kramarz
LIMITED PARTNER
Ameya Vikas Bapat
CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2025 13F record
Q2 2025 13F filing summary
| Period of report | June 30, 2025 |
|---|---|
| Filed | August 14, 2025 |
| Form | 13F-HR |
| Reported value | $1.4B |
| Positions | 33 |
| Change in reported value | +4.4% |
| New positions | 7 |
| Exited positions | 5 |
| Position turnover | 31.6% |
| Top-10 concentration | 62.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
33 | $1.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
36 | $1.7B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
33 | $1.5B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
37 | $2.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
33 | $1.4B |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $1.4B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
36 | $1.6B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $1.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
39 | $1.5B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
32 | $1.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
30 | $855.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
26 | $889.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
32 | $656.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
35 | $663.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
30 | $621.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
24 | $473.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
27 | $447.7M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
25 | $431.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
29 | $379.3M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MRUS MERUS N V | $185.4M | 13.09% |
| 2 | NUVL NUVALENT INC | $104.9M | 7.41% |
| 3 | XENE XENON PHARMACEUTICALS INC | $94.7M | 6.68% |
| 4 | ELVN ENLIVEN THERAPEUTICS INC | $94.1M | 6.64% |
| 5 | AGIO AGIOS PHARMACEUTICALS INC | $77.3M | 5.46% |
| 6 | CLDX CELLDEX THERAPEUTICS INC NEW | $70.2M | 4.96% |
| 7 | ALKS ALKERMES PLC | $70.1M | 4.95% |
| 8 | VRDN VIRIDIAN THERAPEUTICS INC | $68.2M | 4.81% |
| 9 | PTGX PROTAGONIST THERAPEUTICS INC | $59.4M | 4.19% |
| 10 | CDTX CIDARA THERAPEUTICS INC | $57.2M | 4.04% |
| 11 | SRRK SCHOLAR ROCK HLDG CORP | $51.4M | 3.63% |
| 12 | SLNO SOLENO THERAPEUTICS INC | $51.1M | 3.61% |
| 13 | RLAY RELAY THERAPEUTICS INC | $46.2M | 3.26% |
| 14 | NRIX NURIX THERAPEUTICS INC | $45.0M | 3.17% |
| 15 | CNTA CENTESSA PHARMACEUTICALS PLC | $43.3M | 3.06% |
| 16 | PHVS PHARVARIS N V | $33.6M | 2.37% |
| 17 | KYMR KYMERA THERAPEUTICS INC | $32.7M | 2.31% |
| 18 | MNMD MIND MEDICINE MINDMED INC | $32.5M | 2.29% |
| 19 | SYRE SPYRE THERAPEUTICS INC | $29.8M | 2.1% |
| 20 | TYRA TYRA BIOSCIENCES INC | $29.7M | 2.09% |
Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.